Hydroxychloroquine in COVID-19 Treatment, Actual Usage in the USA | US Issues

https://us-issues.com/2020/08/29/hydroxychloroquine-in-covid-19-treatment-actual-usage-in-the-usa/

By Leo Goldstein – Re-Blogged From WUWT

Preprint. August 23, 2020.

Abstract

Three population surveys were performed, seeking information about the drugs prescribed for COVID-19 patients. The August 16 national survey (USA-0816, 868 valid responses) and the August 3 national survey (USA-0803, 1,059 valid responses) covered the entire US. Another smaller survey (TX-0711, 116 valid responses) covered the state of Texas. All responses to all three surveys are attached in anonymized form for further analysis by the scientific community as one of the deliverables.

The analysis was focused on Hydroxychloroquine (HCQ). This study has found that Hydroxychloroquine (HCQ) was used for the treatment of COVID-19 in the US since January 2020. From January to August 16, 13.5% of COVID-19 patients ages 40+ were prescribed Hydroxychloroquine in the US.

The New England and Middle Atlantic census divisions suffered from the largest COVID-19 mortality and accounted for most COVID-19 deaths from mid-March through mid-June. This study has found that they had the lowest utilization of HCQ (average 6.1% for patients ages 40+) in the matching period early March — late May.

Everywhere in the US, prescribing HCQ nearly ceased in the last third of May but resumed in June and have been fluctuating around 16%, for patients ages 40+.

The author declares no competing interest.

No funding was provided for this work.

All relevant ethical guidelines have been followed.

Introduction